{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,7,2]],"date-time":"2026-07-02T23:54:40Z","timestamp":1783036480884,"version":"3.54.6"},"reference-count":40,"publisher":"Frontiers Media SA","license":[{"start":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T00:00:00Z","timestamp":1775692800000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["frontiersin.org"],"crossmark-restriction":true},"short-container-title":["Front. Med."],"abstract":"<jats:sec>\n                    <jats:title>Introduction<\/jats:title>\n                    <jats:p>This study investigated the impact of interstitial lung disease (ILD), a prevalent complication of rheumatoid arthritis (RA), on the achievement of treatment goals in clinical practice under the treat-to-target (T2T) strategy.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Methods<\/jats:title>\n                    <jats:p>This retrospective observational study included patients with newly diagnosed RA who underwent chest computed tomography (CT) within 1 year of RA onset between 2016 and 2022. The presence of ILD was assessed using chest CT imaging. Treatment goals were evaluated at 6, 12, and 24 months after treatment started. The goals were low disease activity (CDAI &amp;lt; 10), low inflammation (CRP &amp;lt; 0.5 mg\/dL), and glucocorticoid (GC)-free status. Then, univariate and multivariate analyses were performed to identify factors impacting goal achievement.<\/jats:p>\n                  <\/jats:sec>\n                  <jats:sec>\n                    <jats:title>Results and discussion<\/jats:title>\n                    <jats:p>\n                      Of the 254 patients, 57 (22.4%) had RA-ILD. Patients with ILD were older, had higher Anti-citrullinated protein antibodies (ACPA) and rheumatoid factor (RF) positivity, used GCs more frequently, and had lower methotrexate usage. At all-time points, patients with ILD were significantly less likely to achieve treatment goals than those without ILD (21.2% vs. 37.8% at 6 months,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05; 25.0% vs. 48.9% at 12 months,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.05; and 21.3% vs. 56.8% at 24 months,\n                      <jats:italic>p<\/jats:italic>\n                      &amp;lt; 0.01). Multivariate analysis showed that ILD, high baseline CRP, and GC use at the start of treatment were independently and negatively associated with treatment goals, with the adverse impact of ILD increasing over time. In conclusion, RA-ILD acts as a substantial barrier to the effective implementation of T2T strategies in RA.\n                    <\/jats:p>\n                  <\/jats:sec>","DOI":"10.3389\/fmed.2026.1756931","type":"journal-article","created":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:11:57Z","timestamp":1775707917000},"update-policy":"https:\/\/doi.org\/10.3389\/crossmark-policy","source":"Crossref","is-referenced-by-count":1,"title":["Interstitial lung disease constitutes a significant treatment burden in patients with rheumatoid arthritis"],"prefix":"10.3389","volume":"13","author":[{"given":"Toshiyuki","family":"Aramaki","sequence":"first","affiliation":[{"name":"Rheumatic Disease Centre, Sasebo Chuo Hospital","place":["Sasebo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kanako","family":"Kojima","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Centre, Sasebo Chuo Hospital","place":["Sasebo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Toru","family":"Michituji","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Ayuko","family":"Takatani","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Kaoru","family":"Terada","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Centre, Sasebo Chuo Hospital","place":["Sasebo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Katsumi","family":"Eguchi","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Centre, Sasebo Chuo Hospital","place":["Sasebo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Yukitaka","family":"Ueki","sequence":"additional","affiliation":[{"name":"Rheumatic Disease Centre, Sasebo Chuo Hospital","place":["Sasebo, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Naoki","family":"Iwamoto","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Atsushi","family":"Kawakami","sequence":"additional","affiliation":[{"name":"Division of Advanced Preventive Medical Sciences, Department of Immunology and Rheumatology, Nagasaki University Graduate School of Biomedical Sciences","place":["Nagasaki, Japan"]}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"1965","published-online":{"date-parts":[[2026,4,9]]},"reference":[{"key":"B1","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/annrheumdis-2015-207524","article-title":"Treating rheumatoid arthritis to target: 2014 update of the recommendations of an international task force.","volume":"75","author":"Smolen","year":"2016","journal-title":"Ann Rheum Dis."},{"key":"B2","doi-asserted-by":"publisher","first-page":"3","DOI":"10.1136\/ard-2022-223356","article-title":"EULAR recommendations for the management of rheumatoid arthritis with synthetic and biological disease-modifying antirheumatic drugs: 2022 update.","volume":"82","author":"Smolen","year":"2023","journal-title":"Ann Rheum Dis."},{"key":"B3","doi-asserted-by":"publisher","first-page":"1049875","DOI":"10.3389\/fmed.2022.1049875","article-title":"Difficult-to-treat rheumatoid arthritis: current concept and unsolved problems.","volume":"9","author":"Watanabe","year":"2022","journal-title":"Front Med."},{"key":"B4","doi-asserted-by":"publisher","first-page":"20","DOI":"10.1136\/annrheumdis-2021-220973","article-title":"EULAR points to consider for the management of difficult-to-treat rheumatoid arthritis.","volume":"81","author":"Nagy","year":"2022","journal-title":"Ann Rheum Dis."},{"key":"B5","doi-asserted-by":"publisher","first-page":"528","DOI":"10.1164\/ajrccm.156.2.9609016","article-title":"Interstitial lung disease in recent onset rheumatoid arthritis.","volume":"156","author":"Gabbay","year":"1997","journal-title":"Am J Respir Crit Care Med."},{"key":"B6","doi-asserted-by":"publisher","first-page":"50","DOI":"10.1080\/14397595.2018.1553265","article-title":"Clinical predictors of inadequate response to conventional synthetic disease-modifying antirheumatic drugs (csDMARDs) including methotrexate (MTX) in untreated rheumatoid arthritis patients: a single-center observational study.","volume":"30","author":"Aramaki","year":"2020","journal-title":"Mod Rheumatol."},{"key":"B7","doi-asserted-by":"publisher","first-page":"31","DOI":"10.1136\/annrheumdis-2020-217344","article-title":"EULAR definition of difficult-to-treat rheumatoid arthritis.","volume":"80","author":"Nagy","year":"2021","journal-title":"Ann Rheum Dis."},{"key":"B8","doi-asserted-by":"publisher","first-page":"11678","DOI":"10.1038\/s41598-023-37452-y","article-title":"Epidemiology and clinical characteristics of interstitial lung disease in patients with rheumatoid arthritis from the JointMan database.","volume":"13","author":"Zhuo","year":"2023","journal-title":"Sci Rep."},{"key":"B9","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1093\/rheumatology\/keab209","article-title":"Characteristics of patients with difficult-to-treat rheumatoid arthritis in clinical practice.","volume":"60","author":"Takanashi","year":"2021","journal-title":"Rheumatology."},{"key":"B10","doi-asserted-by":"publisher","first-page":"2487","DOI":"10.1093\/rheumatology\/keae325","article-title":"Five-year follow-up of patients with difficult-to-treat rheumatoid arthritis.","volume":"64","author":"Takanashi","year":"2025","journal-title":"Rheumatology."},{"key":"B11","doi-asserted-by":"publisher","first-page":"697","DOI":"10.1148\/radiol.2462070712","article-title":"Fleischner society: glossary of terms for thoracic imaging.","volume":"246","author":"Hansell","year":"2008","journal-title":"Radiology."},{"key":"B12","doi-asserted-by":"publisher","first-page":"216","DOI":"10.1136\/thoraxjnl-2013-203843","article-title":"Connective tissue disease related fibrotic lung disease: high resolution computed tomographic and pulmonary function indices as prognostic determinants.","volume":"69","author":"Walsh","year":"2014","journal-title":"Thorax."},{"key":"B13","doi-asserted-by":"publisher","first-page":"98","DOI":"10.1080\/14397595.2018.1442170","article-title":"Radiological fibrosis score is strongly associated with worse survival in rheumatoid arthritis-related interstitial lung disease.","volume":"29","author":"Ito","year":"2019","journal-title":"Mod Rheumatol."},{"key":"B14","doi-asserted-by":"publisher","first-page":"452","DOI":"10.1038\/bmt.2012.244","article-title":"Investigation of the freely available easy-to-use software \u2018EZR\u2019 for medical statistics.","volume":"48","author":"Kanda","year":"2013","journal-title":"Bone Marrow Transplant."},{"key":"B15","doi-asserted-by":"publisher","first-page":"1987","DOI":"10.1007\/s00296-020-04660-y","article-title":"Comparison of the efficacy and safety of biologic agents between elderly-onset and young-onset RA patients: the ANSWER cohort study.","volume":"40","author":"Jinno","year":"2020","journal-title":"Rheumatol Int."},{"key":"B16","doi-asserted-by":"publisher","first-page":"987","DOI":"10.1002\/art.1780280905","article-title":"The clinical features of elderly-onset rheumatoid arthritis. A comparison with younger-onset disease of similar duration.","volume":"28","author":"Deal","year":"1985","journal-title":"Arthritis Rheum."},{"key":"B17","doi-asserted-by":"publisher","first-page":"1472","DOI":"10.1002\/art.40904","article-title":"Rheumatoid arthritis disease activity predicting incident clinically apparent rheumatoid arthritis-associated interstitial lung disease: a prospective cohort study.","volume":"71","author":"Sparks","year":"2019","journal-title":"Arthritis Rheumatol."},{"key":"B18","doi-asserted-by":"publisher","first-page":"1403","DOI":"10.1164\/rccm.201411-1950OC","article-title":"Detection of rheumatoid arthritis-interstitial lung disease is enhanced by serum biomarkers.","volume":"191","author":"Doyle","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B19","doi-asserted-by":"publisher","first-page":"1773","DOI":"10.1093\/rheumatology\/keac584","article-title":"Comorbidities and extra-articular manifestations in difficult-to-treat rheumatoid arthritis: different sides of the same coin?","volume":"62","author":"Dey","year":"2023","journal-title":"Rheumatology."},{"key":"B20","doi-asserted-by":"publisher","first-page":"v1","DOI":"10.1136\/thx.2008.101691","article-title":"Interstitial lung disease guideline: the British thoracic society in collaboration with the thoracic society of Australia and New Zealand and the Irish Thoracic society.","volume":"63","author":"Bradley","year":"2008","journal-title":"Thorax."},{"key":"B21","doi-asserted-by":"publisher","first-page":"e3","DOI":"10.1164\/rccm.201506-1063ST","article-title":"An official ATS\/ERS\/JRS\/ALAT clinical practice guideline: treatment of idiopathic pulmonary fibrosis. an update of the 2011 clinical practice guideline.","volume":"192","author":"Raghu","year":"2015","journal-title":"Am J Respir Crit Care Med."},{"key":"B22","doi-asserted-by":"publisher","first-page":"2000337","DOI":"10.1183\/13993003.00337-2020","article-title":"Methotrexate and rheumatoid arthritis associated interstitial lung disease.","volume":"57","author":"Juge","year":"2021","journal-title":"Eur Respir J."},{"key":"B23","doi-asserted-by":"publisher","first-page":"e028466","DOI":"10.1136\/bmjopen-2018-028466","article-title":"Is incident rheumatoid arthritis interstitial lung disease associated with methotrexate treatment? Results from a multivariate analysis in the ERAS and ERAN inception cohorts.","volume":"9","author":"Kiely","year":"2019","journal-title":"BMJ Open."},{"key":"B24","doi-asserted-by":"publisher","first-page":"803","DOI":"10.1002\/art.38322","article-title":"Methotrexate and lung disease in rheumatoid arthritis: a meta-analysis of randomized controlled trials.","volume":"66","author":"Conway","year":"2014","journal-title":"Arthritis Rheumatol."},{"key":"B25","doi-asserted-by":"publisher","first-page":"1100","DOI":"10.1136\/ard.2008.093690","article-title":"Long-term safety of methotrexate monotherapy in patients with rheumatoid arthritis: a systematic literature research.","volume":"68","author":"Salliot","year":"2009","journal-title":"Ann Rheum Dis."},{"key":"B26","doi-asserted-by":"publisher","first-page":"79","DOI":"10.1007\/s10067-011-1758-6","article-title":"How common is methotrexate pneumonitis? A large prospective study investigates.","volume":"31","author":"Sathi","year":"2012","journal-title":"Clin Rheumatol."},{"key":"B27","doi-asserted-by":"publisher","first-page":"795","DOI":"10.1111\/1756-185X.14351","article-title":"Predictors of progression in rheumatoid arthritis-associated interstitial lung disease: a single-center retrospective study from China.","volume":"25","author":"Liu","year":"2022","journal-title":"Int J Rheum Dis."},{"key":"B28","doi-asserted-by":"publisher","first-page":"877","DOI":"10.4081\/mrm.2022.877","article-title":"Risk factors for rheumatoid arthritis-associated interstitial lung disease: a retrospective study.","volume":"17","author":"Ben Tekaya","year":"2022","journal-title":"Multidiscip Respir Med."},{"key":"B29","doi-asserted-by":"publisher","first-page":"1265355","DOI":"10.3389\/fmed.2023.1265355","article-title":"Progression of radiographic fibrosis in rheumatoid arthritis-associated interstitial lung disease.","volume":"10","author":"Chai","year":"2023","journal-title":"Front Med."},{"key":"B30","doi-asserted-by":"publisher","first-page":"e005615","DOI":"10.1136\/bmjopen-2014-005615","article-title":"Potential risk of TNF inhibitors on the progression of interstitial lung disease in patients with rheumatoid arthritis.","volume":"4","author":"Nakashita","year":"2014","journal-title":"BMJ Open."},{"key":"B31","doi-asserted-by":"publisher","first-page":"256","DOI":"10.1016\/j.semarthrit.2010.11.002","article-title":"Interstitial lung disease induced or exacerbated by TNF-targeted therapies: analysis of 122 cases.","volume":"41","author":"Perez-Alvarez","year":"2011","journal-title":"Semin Arthritis Rheum."},{"key":"B32","doi-asserted-by":"publisher","first-page":"816","DOI":"10.1096\/fj.03-1273rev","article-title":"TGF-beta signaling and the fibrotic response.","volume":"18","author":"Leask","year":"2004","journal-title":"FASEB J."},{"key":"B33","doi-asserted-by":"publisher","first-page":"1085","DOI":"10.1111\/imj.14670","article-title":"Tocilizumab therapy in rheumatoid arthritis with interstitial lung disease: a multicentre retrospective study.","volume":"50","author":"Manfredi","year":"2020","journal-title":"Intern Med J."},{"key":"B34","doi-asserted-by":"publisher","first-page":"64","DOI":"10.1177\/1753465816668780","article-title":"Therapeutic management of patients with rheumatoid arthritis and associated interstitial lung disease: case report and literature review.","volume":"11","author":"Picchianti Diamanti","year":"2016","journal-title":"Ther Adv Respir Dis."},{"key":"B35","doi-asserted-by":"publisher","first-page":"102830","DOI":"10.1016\/j.autrev.2021.102830","article-title":"Efficacy and safety of abatacept in interstitial lung disease of rheumatoid arthritis: a systematic literature review.","volume":"20","author":"Vicente-Rabaneda","year":"2021","journal-title":"Autoimmun Rev."},{"key":"B36","doi-asserted-by":"publisher","first-page":"2195","DOI":"10.3390\/molecules28052195","article-title":"Baricitinib attenuates bleomycin-induced pulmonary fibrosis in mice by inhibiting TGF-\u03b21 signaling pathway.","volume":"28","author":"Gu","year":"2023","journal-title":"Molecules."},{"key":"B37","doi-asserted-by":"publisher","first-page":"114103","DOI":"10.1016\/j.bcp.2020.114103","article-title":"Combined anti-fibrotic and anti-inflammatory properties of JAK-inhibitors on macrophages in vitro and in vivo: perspectives for scleroderma-associated interstitial lung disease.","volume":"178","author":"Lescoat","year":"2020","journal-title":"Biochem Pharmacol."},{"key":"B38","doi-asserted-by":"publisher","first-page":"e22336","DOI":"10.1096\/fj.202101436R","article-title":"Canonical and noncanonical regulatory roles for JAK2 in the pathogenesis of rheumatoid arthritis-associated interstitial lung disease and idiopathic pulmonary fibrosis.","volume":"36","author":"Wang","year":"2022","journal-title":"FASEB J."},{"key":"B39","doi-asserted-by":"publisher","first-page":"119","DOI":"10.3390\/biom13010119","article-title":"The role of JAK\/STAT pathway in fibrotic diseases: molecular and cellular mechanisms.","volume":"13","author":"Liu","year":"2023","journal-title":"Biomolecules."},{"key":"B40","doi-asserted-by":"publisher","first-page":"e233640","DOI":"10.1001\/jamanetworkopen.2023.3640","article-title":"Incidence of interstitial lung disease in patients with rheumatoid arthritis treated with biologic and targeted synthetic disease-modifying antirheumatic drugs.","volume":"6","author":"Baker","year":"2023","journal-title":"JAMA Netw Open."}],"container-title":["Frontiers in Medicine"],"original-title":[],"link":[{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1756931\/full","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,4,9]],"date-time":"2026-04-09T04:12:00Z","timestamp":1775707920000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.frontiersin.org\/articles\/10.3389\/fmed.2026.1756931\/full"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,9]]},"references-count":40,"alternative-id":["10.3389\/fmed.2026.1756931"],"URL":"https:\/\/doi.org\/10.3389\/fmed.2026.1756931","relation":{},"ISSN":["2296-858X"],"issn-type":[{"value":"2296-858X","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,9]]},"article-number":"1756931"}}